MIKE Lynch, the former Autonomy boss, yesterday backed a Swiss DNA analysis firm with an £8m investment.
Sophia Genetics, which specialises in the analysis of DNA in order to diagnose patients, is the latest recipient of investment from Lynch’s $1bn technology fund.
While the company specialises in preventative treatment, it also determines “where to fire to right bullet” in terms of cancer treatment.
The £8m investment was Invoke Capital’s first venture into healthcare, which Lynch claimed was “the beginning of personalised medicine which will be a revolution in healthcare”. The firm said the cash would be used to grow in Europe.